» Articles » PMID: 22855182

Development and Characterization of an Isogenic Cell Line with a Radioresistant Phenotype

Overview
Specialty Oncology
Date 2012 Aug 3
PMID 22855182
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Radiation resistance is a major cause of death in cancer patients. Cancer cells react during radiotherapy by re-programming specific cell functions that may confer resistance to radiation. The understanding of this complex process is hindered due to the lack of appropriate study models. We describe an experimental development of a radioresistant isogenic cancer cell line, and its molecular characterization.

Materials And Methods: A431-cultured cells were irradiated for 7 month until 85 Gy. Then, a selected single cell was left to grow as stable A431-R cell line. Clonogenic assay was used to determine cell survival, the α and β parameters of the LQ model, and the mean inactivation dose. The DNA repair ability of cells was evaluated by pulsed-field electrophoresis method. Differential effect of fractionated radiation was ultimately tested in xenografts. Furthermore, we used a wound healing assay, Western blot for EGFR, AKT and ERK1/2 and ELISA test for vascular endothelial growth factor (VEGF) secretion. Finally we explored CD44 marker and cell cycle distribution.

Results: The established A431-R cell line showed radiation resistance in clonogenic assays, repair of radiation-induced DNA fragmentation and xenografted tumours. The radiation resistance was associated with in vitro higher cell growth and migration, increased levels of former oncoproteins, and secretion of VEGF.

Conclusions: In this model, the emergence of radiation resistance was associated with the acquisition of biological traits that support more aggressive behaviour of cancer cells. We have generated a model that will be useful for mechanistic studies and development of rational treatments against radiation resistance in cancer.

Citing Articles

Multiomics analysis of adaptation to repeated DNA damage in prostate cancer cells.

Challis D, Lippis T, Wilson R, Wilkinson E, Dickinson J, BLACK A Epigenetics. 2023; 18(1):2214047.

PMID: 37196186 PMC: 10193866. DOI: 10.1080/15592294.2023.2214047.


The development of radioresistant oral squamous carcinoma cell lines and identification of radiotherapy-related biomarkers.

Huang J, Meng Q, Liu R, Li H, Li Y, Yang Z Clin Transl Oncol. 2023; 25(10):3006-3020.

PMID: 37029240 DOI: 10.1007/s12094-023-03169-7.


The reversibility of cancer radioresistance: a novel potential way to identify factors contributing to tumor radioresistance.

Kuwahara Y, Tomita K, Roudkenar M, Roushandeh A, Sato T, Kurimasa A Hum Cell. 2023; 36(3):963-971.

PMID: 36745313 DOI: 10.1007/s13577-023-00871-0.


MiR-7-5p Is Involved in Ferroptosis Signaling and Radioresistance Thru the Generation of ROS in Radioresistant HeLa and SAS Cell Lines.

Tomita K, Nagasawa T, Kuwahara Y, Torii S, Igarashi K, Roudkenar M Int J Mol Sci. 2021; 22(15).

PMID: 34361070 PMC: 8348045. DOI: 10.3390/ijms22158300.


Dual Role of Integrin Alpha-6 in Glioblastoma: Supporting Stemness in Proneural Stem-Like Cells While Inducing Radioresistance in Mesenchymal Stem-Like Cells.

Stanzani E, Pedrosa L, Bourmeau G, Anezo O, Noguera-Castells A, Esteve-Codina A Cancers (Basel). 2021; 13(12).

PMID: 34205341 PMC: 8235627. DOI: 10.3390/cancers13123055.


References
1.
Pueyo G, Mesia R, Figueras A, Lozano A, Baro M, Vazquez S . Cetuximab may inhibit tumor growth and angiogenesis induced by ionizing radiation: a preclinical rationale for maintenance treatment after radiotherapy. Oncologist. 2010; 15(9):976-86. PMC: 3228040. DOI: 10.1634/theoncologist.2008-0290. View

2.
Phillips T, McBride W, Pajonk F . The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006; 98(24):1777-85. DOI: 10.1093/jnci/djj495. View

3.
Liang K, Ang K, Milas L, Hunter N, Fan Z . The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys. 2003; 57(1):246-54. DOI: 10.1016/s0360-3016(03)00511-x. View

4.
Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K . DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005; 434(7035):864-70. DOI: 10.1038/nature03482. View

5.
Baro M, De Llobet L, Modolell I, Guedea F, Visa J, Balart J . Development and refinement of a technique using a medical radiation therapy facility to irradiate immunodeficient mice bearing xenografted human tumours. Lab Anim. 2012; 46(4):345-8. DOI: 10.1258/la.2012.011147. View